67-6

51/93

) Okonogi H, Kawamura T, Joh K, Koike K, Miyazaki Y, Ogura M, Tsuboi N, Hirano K, Matsushima M, Yokoo T, Horikoshi S, Suzuki Y, Yasuda T, Shirai S, Shibata T, Hattori M, Akioka Y, Katafuchi R, Hashiguchi A, Hisano S, Shimizu A, Kimura K, Maruyama S1, Matsuo S, Tomino Y: Special IgA Nephrop-athy Study Group: A grading system that predicts the risk of dialysis induction in IgA nephropathy patients based on the combina-tion of the clinical and histological severity. Clin Exp Nephrol. 2019; 23: 16-25.) Suzuki H: Biomarkers for IgA nephropathy on the basis of multi-hit pathogenesis. Clin Exp Nephrol. 2019; 23: 26-31.) Selvaskandan H, Cheung CK, Muto M, Barratt J: New strategies and perspectives on managing IgA nephropathy. Clin Exp Nephrol. 2019; 23: 577-588.) Hagiwara S, Gohda T, Funabiki K, Suzuki Y: Essential points of treatment and examina-tion to prevent diabetic kidney disease aggra-vation. Juntendo Medical Journal. 2019; 65: 529-536.) Suzuki H: Multi-hit pathogenesis of IgA nephropathy. Juntendo Medical Journal. 2019; 65: 537-542.) Gohda T, Murakoshi M, Koshida T, Ichikawa S, Li Z, Adachi E, Sakuma H, Hagiwara S, Funabiki K, Suzuki Y: Concept of diabetic kidney disease –Paradigm shift from albu-minuria-based to GFR-based kidney disease. Juntendo Medical Journal. 2019; 65: 510-516.) Tsuda S, Sameshima A, Sekine M, Kawa-guchi H, Fujita D, Makino S, Morinobu A, Murakawa Y, Matsui K, Sugiyama T, Wata-nabe M, Suzuki Y, Nagahori M, Murashima A, Atsumi T, Oku K, Mitsuda N, Takei S, Miyamae T, Takahashi N, Nakajima K, Saito S: Pre-conception status, obstetric outcome and use of medications during pregnancy of systemic lupus erythematosus (SLE), rheu-Szretter KJ, Ramakrishnan B, Adari H, Deotale KD, Engler F, Shriver Z, Wollacott AM, Suzuki Y, Pereira BJG: A Proliferation Inducing Ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy. Kidney Int. 2019; 96:104-116.) Neufeld M, Molyneux K, Pappelbaum KI, Mayer-Hain S, von Hodenberg C, Ehrchen J, Barratt J, Suzuki Y, Sunderkötter C: Galac-tose deficient IgA1 (GD-IgA1) in skin and serum from patients with skin-limited and systemic IgA Vasculitis. J Am Acad Dermatol. 2019; 81: 1078-1085.) Tawada M, Hamada C, Suzuki Y, Sakata F, Sun T, Kinashi H, Katsuno T, Takei Y, Maruyama S, Honda K, Mizuno M, Ito Y: Effects of long-term treatment with low- GDP, pH-neutral solutions on peritoneal membranes in peritoneal dialysis patients. Clin Exp Nephrol. 2019; 23: 689-699.) Hirano K, Matsuzaki K, Yasuda T, Nishikawa M, Yasuda Y, Koike K, Maruyama S, Yokoo T, Matsuo S, Kawamura T, Suzuki Y: Associ-ation Between Tonsillectomy and Outcomes in Patients with Immunoglobulin A Nephrop-athy. JAMA Netw Open. 2019; 2:e194772.) Barbour SJ, Coppo R, Zhang H, Liu ZH, Suzuki Y, Matsuzaki K, Katafuchi R, Er L, Espino-Hernandez G, Kim SJ, Reich HN, Feehally J, Cattran DC: International IgA Nephropathy Network: Evaluating a New International Risk-Prediction Tool in IgA Nephropathy. JAMA Intern Med. 2019; 179: 942-952.) Io H, Nakata J, Aoyama R, Inoshita H, Nakano T, Ishizaka M, Fukui M, Tomino Y, Suzuki Y: Far-infrared therapy for secondary vascular access patency of hemodialysis patients. Renal Replacement Theraphy. 2019.) Suzuki H, Moldoveanu Z, Julian BA, Wyatt RJ, Novak J: Autoantibodies specific for galactose-deficient IgA1 in IgA vasculitis with nephritis. Kidney Int Rep. 2019; 4: 1717-1724.) Murayama G, Chiba A, Suzuki H, Nomura A, Mizuno T, Kuga T, Nakamura S, Amano H, Hirose S, Yamaji K, Suzuki Y, Tamura N, Miyake S: A Critical Role for Mucosal- Asso- 3 4 5 6 7 8 9ciated Invariant T Cells as Regulators and Therapeutic Targets in Systemic Lupus Erythematosus. Front Immunol. 2019; 10: 2681.〈Reviews〉 1 2 3 4 5 6Obstetrics and Gynecology〈Original Articles〉 1559